Topical administration of regorafenib eye drops: phase I dose‐escalation study in healthy volunteers

AIM: Regorafenib is a multikinase inhibitor under investigation for use in neovascular age‐related macular degeneration. In this phase I study, regorafenib eye drops were administered to healthy volunteers to provide information on safety, tolerability and systemic exposure. METHODS: This was a sing...

Descripción completa

Detalles Bibliográficos
Autores principales: Zimmermann, Torsten, Höchel, Joachim, Becka, Michael, Boettger, Michael K., Rohde, Beate, Schug, Barbara, Kunert, Kathleen S., Donath, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Clinical Trials
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5903260/
https://www.ncbi.nlm.nih.gov/pubmed/29315699
http://dx.doi.org/10.1111/bcp.13502

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5903260/
https://www.ncbi.nlm.nih.gov/pubmed/29315699
http://dx.doi.org/10.1111/bcp.13502

Ejemplares similares